HR and breast cancer: In patients with HR+/HER2+ ABC, we found that the most common treatment was anti-HER2 regimens plus CT-based regimens, consistent with the 2017 and 2018 Chinese Society of Clinical Oncology (CSCO) BC guideline recommendations (5, 13, 23).